[Use of fluticasone/umeclidinium/vilanterol in France: A population based study]

Abstract

Introduction: In France, the fixed combination fluticasone/umeclidinium/vilanterol (FF/UMEC/VI) is prescribed for the treatment of moderate to severe COPD in adults not adequately treated by LABA/LAMA or ICS/LABA dual therapy since 2018. The aim of our study was to describe the characteristics, prescribing trajectories and care pathways of patients prior to their first prescription of FF/UMEC/VI in France.

Methods: A retrospective cohort study included all patients aged over 40years with a first prescription of FF/UMEC/VI between 2018 and 2019 in France using data from the SNDS database. Descriptive analysis were conducted in the 3years preceding initiation of this medication.

Results: Of the 34,906 patients included, 92% had received a prescription for dual or triple therapy in the 3years prior to starting FF/UMEC/VI. The mean age at inclusion was 69, with a majority of men. A description of the care pathway showed that 68% of patients had moderate exacerbations and 25% had severe exacerbations leading to hospitalization.

Conclusions: Our results demonstrate that triple inhaled therapy with FF/UMEC/VI is used in accordance with its marketing authorization in France in the vast majority of cases.

Keywords: BPCO; COPD; Claims database; Fluticasone furoate/umeclidinium/vilanterol; Pharmaco-épidémiologie; Pharmacoepidemiology; Pneumologie; Pneumology; SNDS.